ABOS News and Press, Acumen Pharmaceuticals Inc. From 07/30/22

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company wi...

Gainers: Redbox Entertainment ( RDBX ) +100% . Nano Labs ( NA ) +86% . FaZe ( FAZE ) +42% . Koss Corporation ( KOSS ) +35% . SpringBig Holdings ( SBIG ) +31% . Infrastructure and Energy Alternatives ( IEA ) +31% . ...

Mid- and late-stage data readouts over the last few years for Alzheimer's therapies have had a similar theme: Failure. Almost all these candidates have one thing in common: They target reducing beta-amyloid plaque in the brain that is thought to play a role in the memory-robbing dis...

H.C. Wainwright has initiated Acumen Pharmaceuticals ( NASDAQ: ABOS ) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise. The firm has a $15 price target (~207% return based on Wednesday's closing price). Unlike many other A...

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Conference Call May 16, 2022, 04:30 PM ET Company Participants John Woolford - IR, Westwicke Daniel O'Connell - President & CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participan...

Image source: The Motley Fool. Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q1 2022 Earnings Call May 16, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Tran...

Acumen Pharmaceuticals press release (NASDAQ:ABOS): Q1 GAAP EPS of -$0.23 misses by $0.06. Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 i...

Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease Frontiers in Neuroscience ...

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company wil...